• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Don't Abandon the Biotech Ship

There's too much good out there.
By JIM CRAMER Dec 01, 2015 | 05:16 AM EST
Stocks quotes in this article: REGN, UNH, AMGN, CVS, CELG, BMY, RCPT, BIIB, GILD, AGN, PFE, ABBV, ABT

The all-or-nothing relationship this market has with biotech is stupefying. Consider yesterday. Regeneron (REGN) was tagged for an 18-point loss, yet UnitedHealth (UNH) decided to favor its anti-cholesterol drug over that of Amgen's (AMGN). That's a gigantic deal, and one that says those who sold Regeneron when CVS (CVS) gave its contract to Amgen, should re-think their stance.

Celgene (CELG) rolled over again, this time presumably because of a challenge to its blood cancer franchise by Bristol-Myers (BMY). BMY is a very strong competitor and it is true that Revlimid, Celgene's offering, came in a tad light last vs. expectation, but we are still at the cusp of what the drugs from Receptos (RCPT) will bring to the franchise.

Action Alerts PLUS charity portfolio holding Biogen (BIIB) roared Friday. Maybe that's why it sold off on Monday? Gilead (GILD), if you read Twitter, seemed like it was about to have a breakout on Friday.

Instead, it had a breakdown on Monday. That's why this group seems to have become investible. The volatility is insane. Plus, the company that was rumored to be on the prowl to buy one of these or Amgen, and here I am talking about Allergan (AGN), has said that game's over. It's wedded to Dividend Stock Advisor portfolio name Pfizer (PFE), and has more of an AbbVie (ABBV)-Abbott (ABT) break-up in front of it than anything involving the takeover of these biotechs.

In that world, where fickle is the watchword and rigorous long-term thinking is all but banned, what do you do?

I continue to believe that Gilead will be able to take the money it is getting from its Hepatitis C franchise and grow à la Pharmasset, via acquisitions, as per Celgene. I don't think Celgene's Revlimid franchise is in doubt. Our trust has a substantial position in Biogen, because it is just too cheap.

In other words, don't abandon ship. There's too much good out there, and while it is overshadowed by the current bad, all of these companies do have earnings power and balance sheets that are good, and therefore are not to be trifled with, or sold if you own them.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long BIIB, AGN.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Bearish Bets: 3 Stocks You Should Really Consider Shorting This Week

Bob Lang
May 28, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

These Small-Cap Biotech Stocks Have the Wind at Their Back

Bret Jensen
May 24, 2023 1:30 PM EDT

After getting a 'win' earlier this week on an acquisition, let's highlight a few similar names in my portfolio.

Why Are CRISPR Therapeutics Charts Saying 'Buy'?

Bruce Kamich
May 15, 2023 1:00 PM EDT

Here's where traders could go long.

Is It Time to Get Back Into CVS Health? Here's a Trade Idea

Stephen Guilfoyle
May 15, 2023 10:30 AM EDT

The fundamentals are not in tip-top shape, and now investors have reduced guidance to deal with.

Bearish Bets: 3 Well-Known Stocks You Should Consider Shorting This Week

Bob Lang
May 14, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:48 AM EDT CHRIS VERSACE

    Latest AAP Podcast With Portillo's CEO!

    Listen in as we talk with a rising star in the Chi...
  • 03:25 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Don't Just Sit There and 'Hope' for Your Stocks, M...
  • 07:32 AM EDT BOB LANG

    Webinar Thursday After the Close: Option Spread Trading

    Thursday, my good friend and colleague Sam DeMarco...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login